Judit González-Gallego
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Judit González-Gallego has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Ali Erturk
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
1 shared publicationBarbara Lindner
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
1 shared publicationCarolina Cardoso Gonçalves
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
1 shared publicationDennis Crusius
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany
1 shared publication- Dominik Paquet
Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, 81377 Munich, Germany
1 shared publication - Georg Kislinger
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (2) , 479-492
A fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions
Blood–brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.
- 15 December 2025
- Published by Springer Nature in Nature Neuroscience
- Vol. 29 (2) , 479-492
Open AccessA fully iPS-cell-derived 3D model of the human blood–brain barrier for exploring neurovascular disease mechanisms and therapeutic interventions
Blood–brain barrier (BBB) integrity is critical for brain homeostasis, with malfunctions contributing to neurovascular and neurodegenerative disorders. Mechanistic studies on BBB function have been mostly conducted in rodent and in vitro models, which recapitulate some disease features, but have limited translatability to humans and pose challenges for drug discovery. Here we report on a fully human induced pluripotent stem (iPS)-cell-derived, microfluidic three-dimensional (3D) BBB model consisting of endothelial cells (ECs), mural cells and astrocytes. Our model expresses typical fate markers, forms a barrier in vessel-like tubes and enables perfusion, including with human blood. Deletion of FOXF2 in ECs, a major risk gene for cerebral small vessel disease, induced key features of BBB dysfunction, including compromised cell junction integrity and enhanced caveolae formation. Proteomic analysis revealed dysregulated endocytosis and cell junction pathways. Disease features phenocopied those seen in mice with EC-specific Foxf2 deficiency. Moreover, lipid-nanoparticle-based treatment with Foxf2 mRNA rescued BBB deficits, demonstrating the potential for drug development.